Ninety One UK 13F: Adds $62M to NBIX Stake

Institutional investor Ninety One UK significantly expanded its footprint in Neurocrine Biosciences, Inc. (NasdaqGS: NBIX), according to a Form 13F filing with the SEC on October 15, 2026. Because 13F reports look backward at a prior quarter's end, these numbers capture portfolio choices made earlier and may not show the firm's exact current balance today.

What Changed in Ninety One UK's Neurocrine Biosciences Position

Ninety One UK boosted its holdings in the drugmaker by a striking 160,372.7%, adding 434,610 shares to its portfolio. The fund finished the reported period with 434,881 shares of Neurocrine Biosciences, carrying a reported market value of about $61.7 million. That follows a tiny starting stake of just 271 shares.

Other Institutional Activity in Neurocrine Biosciences

Other large money managers also tweaked their bets on the healthcare company. Blackrock Inc. grew its holdings by 326,594 shares, ending with 13,711,607 shares worth about $1.86 billion. JPMORGAN CHASE & CO added 956,699 shares for a 17.6% increase, finishing with 6,398,674 shares valued at roughly $868.4 million. Dodge & Cox Inc. grew its holdings by 123,425 shares, ending with 5,584,707 shares worth about $757.9 million. Vanguard Portfolio Management LLC grew its holdings by 247,664 shares, ending with 4,974,083 shares worth about $675.0 million. Vanguard Capital Management LLC grew its holdings by 33,388 shares, ending with 4,545,339 shares worth about $616.8 million.

Neurocrine Biosciences, Inc. Stock Down 0.8%

Neurocrine Biosciences shares recently traded around $135.90. The stock sits below its 50-day moving average of $149.74 and its 200-day moving average of $147.06. Shares have traded between a 52-week low of $122.14 and a 52-week high of $186.12.

Recent Earnings

Neurocrine Biosciences pulled in $3.37 billion in trailing-twelve-month revenue with earnings of $6.82 per share. The company reported a net margin of 20.9% and a return on equity of 22.1%. Its next quarterly financial update is scheduled for November 2, 2026.

Insider Buying and Selling at Neurocrine Biosciences, Inc.

Company insiders were active in the stock earlier in the year. Chief Legal Officer Darin Lippoldt bought 200 shares at $81.49 on June 26, 2026, worth $16,298. On June 29, 2026, Lippoldt bought another 9,800 shares at $81.49 for a total of $798,602, and also bought an additional 9,800 shares at the same price. On that same date, Lippoldt sold 9,800 shares at an average price of $170.16 under a planned trading strategy, bringing in about $1.67 million.

Analysts Set New Price Targets

Wall Street firms maintain varied outlooks on the drug developer. On September 3, 2026, Citigroup maintained its Buy rating with a $253.00 price target. RBC Capital reiterated its Outperform rating at $198.00 on September 8, 2026. Morgan Stanley maintained an Equal-Weight rating with an $183.00 target on September 11, 2026. UBS kept a Buy rating on September 29, 2026, lowering its target from $231.00 to $214.00. BMO Capital maintained a Market Perform rating while trimming its target from $164.00 to $150.00 on October 12, 2026. The stock carries a consensus strong buy rating with a mean price target of $206.81 across 29 analyst opinions.

About Neurocrine Biosciences

Headquartered in San Diego, California, Neurocrine Biosciences discovers, develops, and brings to market specialty pharmaceutical treatments for neurological, psychiatric, endocrine, and immunological conditions. The company relies on its research pipeline to deliver therapies for underserved medical populations in the United States and across international markets.

Bottom Line

Investors tracking Ninety One UK will want to see if the fund continues building its position in upcoming SEC filings. The company's next earnings report on November 2, 2026, will provide fresh financial data on its drug portfolio and profit margins. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.